Overview

Sirolimus Use in Angioplasty for Vascular Access Extension

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure.
Phase:
Phase 2
Details
Lead Sponsor:
Lawson Health Research Institute
Collaborator:
Pfizer
Treatments:
Everolimus
Sirolimus